The drug maker has said that its antibody treatment for Covid-19 met its main goals in a late-stage trial, helping reduce severe Covid-19 or death in non-hospitalised patients.
AstraZeneca’s new drug halves Covid-19 deaths in new trial
Share
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.